Myocardial fibrosis in athletes:Additional considerations by Małek, Łukasz A & Bucciarelli-Ducci, Chiara
                          Małek, Ł. A., & Bucciarelli-Ducci, C. (2020). Myocardial fibrosis in
athletes: Additional considerations. Clinical cardiology.
https://doi.org/10.1002/clc.23466
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1002/clc.23466
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Wiley at
https://onlinelibrary.wiley.com/doi/full/10.1002/clc.23466 . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
L E T T E R T O TH E E D I T O R
Myocardial fibrosis in athletes: Additional considerations
Dear Editor,
We would like to thank Martin et al1 for their interest with our recent
review on the current perspective in myocardial fibrosis in athletes
and the provided comments.2 In their letter, the authors suggest that
hypertrabeculation should be included as another expression of the
athlete's heart after careful differentiation from left ventricular non-
compaction (LVNC).3 Furthermore, they point out on isolated
arrhythmogenic left ventricular dysplasia, which, as they postulate,
should be included separately in the differentiation between normal
and abnormal imaging findings in athletes.
Our review was mainly focused on the summary and discussion
of most common patterns of fibrosis observed in asymptomatic ath-
letes described in the observational studies, including nonischemic
insertion-point fibrosis or small mid-wall/subepicardial fibrosis and
small ischemic-type fibrosis (mostly in veteran athletes). Those pat-
terns are usually found in athletes with otherwise normal hearts or
presenting features of an athlete's heart defined as a physiological
adaptation to physical exercise including balanced enlargement of
heart chambers with or without mild left ventricular hypertrophy.4
Enlarged ventricles lead to the extension of existing trabeculae, which
may appear as hypertrabeculation, but as there is not true structural
change to the heart, these feature is not typically considered as a part
of an athlete's heart. Apart from lack of symptoms, athletes with
incidentally found small fibrosis usually have normal electrocardio-
gram (ECG), lack of significant arrhythmia and normal physical
capacity.
In the last part of our review, we present how fibrosis detection
and other cardiac magnetic resonance (CMR) markers can be used to
distinguish between athlete's heart and pathology including
arrhythmogenic right ventricular hypertrophy (ARVC). ARVC may
include the cases of isolated arrhythmogenic left ventricular dysplasia
and for this reason, it is recently referred to as simply arrhythmogenic
cardiomyopathy.4 These athletes may also have nonischemic patterns
of fibrosis in the left ventricle as pointed out in the review. However,
they are usually accompanied by other CMR features atypical for the
athlete's heart. Athletes suspected of cardiomyopathy are also more
likely to present symptoms, to have changes on resting ECG, accom-
panying arrhythmia and/or decreased physical performance. All this
information should be taken into account in the assessment of ath-
letes suspected of pathology, with CMR being only one of the
supporting imaging methods in that process.
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